Targeting acute hypoxic cancer cells by doxorubicin-immunoliposomes directed by monoclonal antibodies specific to RON receptor tyrosine kinase. - Wikidata - wikimedia - TriplyDB

Targeting acute hypoxic cancer cells by doxorubicin-immunoliposomes directed by monoclonal antibodies specific to RON receptor tyrosine kinase.

Targeting acute hypoxic cancer cells by doxorubicin-immunoliposomes directed by monoclonal antibodies specific to RON receptor tyrosine kinase.

http://www.wikidata.org/entity/Q39676024

about

Deletion or insertion in the first immunoglobulin-plexin-transcription (IPT) domain differentially regulates expression and tumorigenic activities of RON receptor Tyrosine Kinase.Molecular-genetic imaging of cancer.Biological evaluation of antibody-maytansinoid conjugates as a strategy of RON targeted drug delivery for treatment of non-small cell lung cancer Monoclonal antibody Zt/g4 targeting RON receptor tyrosine kinase enhances chemosensitivity of bladder cancer cells to Epirubicin by promoting G1/S arrest and apoptosis.Strategies of targeting the extracellular domain of RON tyrosine kinase receptor for cancer therapy and drug delivery.Orally administered liposomal formulations for colon targeted drug delivery.ADAM17-overexpressing breast cancer cells selectively targeted by antibody-toxin conjugates.

P2860

Q34405019-017C285C-0AD3-4306-8A25-54B13E75D2A6 Q35116121-7801E78F-99EE-4D7C-B3E6-8F450DB98CEE Q36824455-96625A4E-A611-4886-AAB1-2C8AF7B613DA Q37707571-FD38052C-2BB0-49E1-B86B-EA69CEA1C05F Q38922319-6D2B7051-2AE3-4D77-98A6-E60993099E16 Q40475538-F7268931-BEFE-4928-A1B9-4A10C272A0DE Q47197303-4FCC2077-E8AA-4B37-923C-EFEA16F48AF2

P2860

Targeting acute hypoxic cancer cells by doxorubicin-immunoliposomes directed by monoclonal antibodies specific to RON receptor tyrosine kinase.

http://www.wikidata.org/entity/Q39676024

description

2010 nî lūn-bûn

@nan

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

2010年论文

@zh

2010年论文

@zh-cn

name

Targeting acute hypoxic cancer ...... RON receptor tyrosine kinase.

@en

Targeting acute hypoxic cancer ...... RON receptor tyrosine kinase.

@nl

type

label

Targeting acute hypoxic cancer ...... RON receptor tyrosine kinase.

@en

Targeting acute hypoxic cancer ...... RON receptor tyrosine kinase.

@nl

prefLabel

Targeting acute hypoxic cancer ...... RON receptor tyrosine kinase.

@en

Targeting acute hypoxic cancer ...... RON receptor tyrosine kinase.

@nl

P1433

Q39676024-9DCA56D2-5BED-41A7-A5EB-0B446E605936

P1476

Q39676024-B42B9C3E-E50F-4152-9DEA-FEFCB2F5A13C

P2093

Q39676024-1C384AB3-912B-4DD4-8E5B-644BAAC62C6A

Q39676024-2D63C389-60AE-4DC7-8306-F87143479729

Q39676024-6595DAF5-36EC-42DA-A2B2-332705CD3E54

Q39676024-BC3612AE-EA00-423A-8DC6-4BEFDEDED925

Q39676024-F50FE355-78D5-4014-8B9F-D1BD9C6AB31A

Q39676024-FB186614-4942-4045-9850-E1565474D9A6

P2860

Q39676024-09B9A24F-674A-468D-99DC-49F176AB6DC4

Q39676024-0B1EE50E-0F02-4F36-BE77-B6A01C8B5BEE

Q39676024-10325522-58E6-42B1-BD67-E2ADC4408E85

Q39676024-1181D0B4-221D-4E64-AA1E-CC42ECA4247A

Q39676024-1949B24B-C84A-4A79-81A4-F621FA0655D0

Q39676024-1BF85DFE-81E7-4398-A4AF-FB77BC43870A

Q39676024-1C3A8F2A-0F5F-45C2-947C-95EF3681AD06

Q39676024-1FF76474-4062-4558-B85D-3070D482A813

Q39676024-218BE124-73CC-406D-A74B-7FD44769EEAD

Q39676024-24E1EC3A-3CB6-42FE-8060-B5E6B8E167D7

P2888

Q39676024-E50FC378-CF71-42E4-AE27-AAB55F3CFEEC

P304

Q39676024-8BC6CA82-5052-479D-A412-1A1CE1F25657

P31

Q39676024-D810D06D-F50B-429B-AB7B-11E83A3928D8

P356

Q39676024-3B77A0A3-CE76-413D-8A82-0B618509FB9A

P433

Q39676024-93A2D45C-B8B9-47C9-9C88-E2875F23C333

P478

Q39676024-6877B76F-11F9-4972-BD1A-5DB4FAC2D1F7

P577

Q39676024-AE24DE32-8246-4B9F-815E-9522370A8E02

P698

Q39676024-326169A3-B241-464E-AE9F-11DB610DBB33

P921

Q39676024-622D4AF0-126A-469A-ACE1-8489D797D243

Q39676024-980AE967-AC49-4385-A361-D12E7BD44141

P356

S00280-010-1408-8

P1433

Cancer Chemotherapy and Pharmacology

P1476

Targeting acute hypoxic cancer ...... RON receptor tyrosine kinase.

@en

P2093

Hang-Ping Yao

http://www.w3.org/2001/XMLSchema#string

Ming-Hai Wang

http://www.w3.org/2001/XMLSchema#string

Qi Ma

http://www.w3.org/2001/XMLSchema#string

Snehal Padhye

http://www.w3.org/2001/XMLSchema#string

Sunny Guin

http://www.w3.org/2001/XMLSchema#string

Yong-Qing Zhou

http://www.w3.org/2001/XMLSchema#string

P2860

Identification of the ron gene product as the receptor for the human macrophage stimulating protein

Targeting HIF-1 for cancer therapy

Improving the efficacy of antibody-based cancer therapies

Exploiting tumour hypoxia in cancer treatment

Therapeutic nanoparticles for drug delivery in cancer

Hypoxia--a key regulatory factor in tumour growth

Drug resistance and the solid tumor microenvironment

Defining the role of hypoxia-inducible factor 1 in cancer biology and therapeutics

Therapeutic implications of a human neutralizing antibody to the macrophage-stimulating protein receptor tyrosine kinase (RON), a c-MET family member.

Met-related receptor tyrosine kinase Ron in tumor growth and metastasis.

P2888

s00280-010-1408-8

P304

1073-1083

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S00280-010-1408-8

http://www.w3.org/2001/XMLSchema#string

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

67

http://www.w3.org/2001/XMLSchema#string

P577

2010-07-25T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

20658288

http://www.w3.org/2001/XMLSchema#string

P921